| Today’s Big NewsApr 9, 2024 |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
| By Angus Liu In December, when Merck revealed that Lynparza didn't add benefits to Keytruda in certain non-small cell lung cancer patients, the trial appeared to be a complete failure. Although the study itself is beyond salvaging, detailed data now raise some hope for the combination in the future. |
|
|
|
By James Waldron Just months after Bristol Myers Squibb boarded Karuna for its much-hyped schizophrenia drug, the biotech’s leadership has set sail in a new venture. |
By Conor Hale The largest randomized trial to compare Medtronic’s Evolut and Edwards’ Sapien TAVR implants is also the first to primarily focus on women. |
By Annalee Armstrong First-in-human results for AstraZeneca's saruparib showed an objective response rate of 48.8% in the 31 evaluable patients at the target dose. Median progression-free survival was 9.1 months. |
|
Tuesday, April 23, 2024 | 1pm ET / 10am PT Join us as we dive into the pivotal challenges facing clinical trial enrollment today. Learn about innovative strategies and solutions for quickly identifying the right patients for specific therapies, the optimal time in their health journey to engage, and how to successfully activate them for trial enrollment. Register now. 
|
|
By Fraiser Kansteiner Even as Novartis rolls ahead with a global restructuring campaign targeting thousands of job cuts, the Swiss drug giant has blueprinted several hundred layoffs in its development organizational unit. |
By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket. |
By Andrea Park In yet another C-suite shift for Bayer’s consumer health business, the division’s North America segment has appointed a new chief marketing officer. |
By Conor Hale Hot on the heels of a $110 million fundraising round earlier this year, Medical Microinstruments has now received a groundbreaking green light from the FDA for its robotic surgery system. |
By Fraiser Kansteiner As Pfizer races to grow the RSV vaccine market along with rival GSK, the company has been looking to expand its vaccine's reach. Now, with fresh data for Abrysvo in adults at higher risk of disease, the New York drugmaker is plotting a new approval filing. |
By Annalee Armstrong When a rare solar eclipse passes overhead, what’s a scientist to do, but stop and take a look? |
By Conor Hale Q Bio aims to have people reconsider the possibilities of an MRI machine, with an advance in computing that could one day enable new uses for the diagnostic imaging hardware. |
By Angus Liu At an FDA advisory committee meeting this Friday, two teams will present their studies examining the utility of minimal residue disease (MRD) as a potentially approvable endpoint in multiple myeloma. For this report, Fierce Pharma spoke with experts to learn about what's at stake, including the need to bring new treatments to patients earlier. |
By Nick Paul Taylor CG Life has found what it is looking for in Toolhouse, inking a deal to buy the digital agency for the tools to chisel out the next chapter in its story. |
By Fraiser Kansteiner Ascend, which bills itself as a “total solutions gene therapy development partner,” has picked up the manufacturing team and site of Beacon Therapeutics in Alachua, Florida. As part of the deal, Ascend has also agreed to a long-term partnership with Beacon to produce its ocular gene therapies for clinical and commercial use. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of Peripheral Vascular Intervention & CLI Program at Rush University Medical Center, to explore peripheral arterial disease—a serious health issue that is often overlooked and undermanaged. |
|
|---|
|
|
|
Tuesday, April 30, 2024 | 2pm ET / 11am PT Liquid biopsies have shown tremendous progress for the early detection of cancer and for treatment monitoring, but still have limitations. The inclusion of protein glycosylation can help. Join us to learn more about the latest solutions for leveraging AI and machine learning to accelerate data processing, overcome current barriers, and provide crucial information. Register now. 
|
|
eBook Unlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
